Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00866944 | Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases | PHASE2 | COMPLETED | 35 | — | — | Mar 1, 2009 | Nov 1, 2011 | Nov 11, 2011 | 16 | France, Germany |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Adecatumumab alone |
| 2 | EXPERIMENTAL | FOLFOX 4 followed by Adecatumumab |
| 3 | ACTIVE_COMPARATOR | FOLFOX 4 alone |
| Name | Type | Description |
|---|---|---|
| Adecatumumab | DRUG | Adecatumumab,6-9mg/kg, every 14 days, 24 cycles |
| Adecatumumab and FOLFOX | DRUG | FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles |
| FOLFOX 4 | DRUG | FOLFOX 4, every 14 days, 12 cycles |
Inclusion Criteria: * Histopathologically confirmed complete resection (R0) of liver metastases from colorectal adenocarcinoma * Age ≥18 years * ECOG performance status ≤ 2 * Patient was informed, has read and understood the patient information / informed consent form and has given written informed...